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DOI 10.1186/s12913-017-2215-2RESEARCH ARTICLE Open AccessAvoidable costs of stenting for aortic
coarctation in the United Kingdom: an
economic model
Maximilian Salcher1* , Alistair Mcguire1, Vivek Muthurangu2, Marcus Kelm3, Titus Kuehne3, Huseyin Naci1
and CARDIOPROOFAbstract
Background: Undesirable outcomes in health care are associated with patient harm and substantial excess costs.
Coarctation of the aorta (CoA), one of the most common congenital heart diseases, can be repaired with stenting
but requires monitoring and subsequent interventions to detect and treat disease recurrence and aortic wall injuries.
Avoidable costs associated with stenting in patients with CoA are unknown.
Methods: We developed an economic model to calculate potentially avoidable costs in stenting treatment of CoA in
the United Kingdom over 5 years. We calculated baseline costs for the intervention and potentially avoidable complications
and follow-up interventions and compared these to the costs in hypothetical scenarios with improved treatment
effectiveness and complication rates.
Results: Baseline costs were £16 688 ($25 182) per patient. Avoidable costs ranged from £137 ($207) per patient in a
scenario assuming a 10% reduction in aortic wall injuries and reinterventions at follow-up, to £1627 ($2455) in a Best-
case scenario with 100% treatment success and no complications. Overall costs in the Best-case scenario were 90.2% of
overall costs at Baseline. Reintervention rate at follow-up was identified as most influential lever for overall costs.
Probabilistic sensitivity analysis showed a considerable degree of uncertainty for avoidable costs with widely
overlapping 95% confidence intervals.
Conclusions: Significant improvements in the treatment effectiveness and reductions in complication rates are
required to realize discernible cost savings. Up to 10% of total baseline costs could be avoided in the best-case
scenario. This highlights the need to pursue patient-specific treatment approaches which promise optimal outcomes.
Keywords: Coarctation of the aorta, Stents, Heart defects, Congenital, Avoidable costs, Cost savingsBackground
Despite a relatively low incidence of 96 per 10,000 live
births [1], patients with congenital heart disease (CHD)
consume a disproportionately large share of health care
spending. Following often expensive primary surgery
most patients can lead a normal life. However, the need
for close monitoring and reinterventions at follow-up
incur substantial costs. Hospital admissions among
adults with CHD are 3.5 times more frequent than in
the general population and at least half of all adult CHD* Correspondence: m.salcher@lse.ac.uk
1LSE Health and Social Care, Cowdray House; London School of Economics
and Political Science, Houghton Street, London WC2A 2AE, UK
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(http://creativecommons.org/publicdomain/zepatients is hospitalized over a 5-year period [2, 3]. Treat-
ment complications further contribute to high resource
use. An American multicentre study found that compli-
cations and extended hospital stay after surgery for CHD
were associated with an average excess cost per case of
$56 584 ($132 483 for major complications) [4]. Another
study found complications to be associated with a 3-fold
risk of high resource utilization (above the 90th percent-
ile) in CHD patients undergoing surgery [5].
Costs associated with undesirable outcomes, including
treatment complications and reinterventions, can be
quantified as avoidable costs. A clinical area where the
economic impact of adverse effects can be studied is co-
arctation of the aorta (CoA), one of the most commonle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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associated with morbidity even after successful repair
[6–8]. Implementation of a stent is an effective option to
repair the obstructed site of the aorta, yet patients are
still at risk of experiencing serious complications while
undergoing treatment, and outcomes at follow-up show
scope for significant improvement. Recurrent CoA and
aortic wall injuries contribute to a reintervention rate
after stenting of approximately 14% at follow-up [9].
The costs associated with undesirable outcomes in-
cluding treatment-related complications of stenting
among individuals with CoA are unknown. Our object-
ive in this paper is to quantify the costs associated with
such potentially avoidable outcomes.
Methods
We developed an economic model to calculate the ex-
pected costs associated with stenting for CoA in the
United Kingdom on a per patient basis. We included im-
portant costs of the initial intervention and monitoring,
as well as costs of complications and follow-up interven-
tions that are potentially amenable to improvements in
stenting repair of CoA. We specified four hypothetical
scenarios of improved treatment outcomes and com-
pared the costs of each scenario to the baseline costs to
obtain estimates of avoidable costs. Three scenarios were
based on potential increases in stenting treatment suc-
cess and reductions in complications and reintervention
rates. The last scenario represents the ‘ideal’ scenario in
which the probability of treatment success is 100% and
no complications and reinterventions occur.Fig. 1 Analytical approach and model structure illustrating alternative events an
between the Baseline scenario and four hypothetical scenarios of improved tre
same events at initial intervention, short-term, and mid-term follow-up.
shows possible events in the first period of the model (during or imm
follow-up. The same events are included for short- and mid-term follow
any other events and are therefore not connected to the other events. Hyper
not impact on complications or reintervention rates itself. Imaging is recomm
circles indicate event probabilities subject to change in scenarios. Dotted circStructure of the model
The analytical approach of comparing expected costs in the
Baseline scenario, Scenarios 1–3, and Best-case scenario, is
presented in Fig. 1. The model structure of events and se-
quelae remained constant for all scenarios, with varying
probabilities for events subject to change in the scenarios.
Figure 1 depicts the model during initial intervention
and at follow-up. Since all patients undergo stenting, the
model consists exclusively of chance nodes and branches
emanating from this treatment decision. Each chance node
has a set of mutually exclusive events which are displayed
in the model structure as boxes. Each event is associated
with costs. The value of each chance node is determined
by the probabilities and costs attached to its events.
The first chance node in the model is success at the ini-
tial stenting intervention. Stenting success is defined as
achieving a post-treatment blood pressure gradient
≤20 mmHg, which represents the threshold for interven-
tion indication in patients with CoA [10, 11]. Aortic wall
injuries caused by the catheter or dilatation of the stenotic
aortic segment are possible despite successful gradient re-
duction, as indicated by the next chance node. In this
model, we only included aortic wall injuries that warrant
intervention. In some cases, aneurysms will develop over
the years following the intervention. In order to assign a
cost to these complications, our model includes them at
the time when they require treatment, i.e. either immedi-
ately after the initial intervention, or at short- or mid-term
follow-up. The branch of aortic wall injuries leads to a
chance node where repair of the injury is conducted either
percutaneously or surgically.d their sequelae. The primary outcome of this analysis is difference in costs
atment effectiveness and patient safety. All scenarios include the
Scenarios differ in the probabilities attached to events. The figure
ediately after the initial intervention), and at short- and mid-term
-up. Hypertension medication and imaging are not dependent on
tension is not directly influenced by other events at follow-up and does
ended for all patients after CoA repair at least every two years [10]. Full
les indicate exogenous event probabilities
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model, we assumed that patients who did not achieve a
post-intervention treatment gradient ≤20 mmHg under-
went a second intervention, which could be either repeat
stenting or surgery. The branch for repeat stenting then
leads to a chance node of experiencing an aortic wall in-
jury, and further to the percutaneous or surgical treat-
ment of the injury.
The model includes the same events for the short-term
and mid-term follow-up period, although different prob-
abilities are assigned to them according to the specific
period. The branches emanating from the first chance node
at follow-up are either no reintervention or reintervention
due to aortic wall injuries or recurrence of coarctation. The
branch for reintervention for re-coarctation is identical to
that after successful stenting at the initial intervention. The
branch for reintervention due to aortic wall injury leads to
a chance node of percutaneous or surgical treatment.
We applied a 5-year timeframe for our analysis, distin-
guishing between costs and events during or immediately
after the initial treatment; during short-term follow-up
(3–18 months); and mid-term follow-up (18 months–Table 1 Event probabilities
Probability estimate
Event
Treatment success after stenting 0.967
Intervention after unsuccessful stenting:
Repeat stenting 0.5
Surgery 0.5
Aortic wall injury after stenting 0.008
Intervention after aortic wall injury:
Percutaneous treatment 0.9
Surgery 0.1
Short-term follow-up
Imaging 1
Patients requiring anti-hypertension medication 0.43
Patients requiring reintervention 0.091
Reintervention for aortic wall injury 0.1
Reintervention for re-coarctation 0.9
Mid-term follow-up
Imaging 1
Patients requiring anti-hypertension medication 0.389
Patients requiring reintervention 0.185
Reintervention for aortic wall injury 0.5
Reintervention for re-coarctation 0.955 years). Expected costs were obtained for each of these
three time periods separately. Discounting the results at
short- and mid-term follow-up, we also calculated ex-
pected overall costs over a 5-year period. The time frame
was chosen due to limited availability of reliable data be-
yond 5 years of follow-up.
Actuarial survival of non-infant patients after CoA
stenting repair is almost 100% even 10 years after treatment
[12]. We assumed no mortality in the model period. Since
there is no loss to mortality in the transition between initial
intervention, short-term, and mid-term follow-up, all three
time periods can be combined to give the overall expected
costs of the treatment over a course of 5 years.
Model input
Baseline values for event probabilities and costs are pre-
sented in Tables 1 and 2, respectively.
Event probabilities
Estimates of event probabilities were derived primarily
from a meta-analysis comparing the effectiveness of
stenting and balloon dilatation in CoA patients [9]. ForSD Distribution Source
0.0128 Beta [9]
0.1 Beta Assumption
0.1 Beta Assumption, inverse probability of
repeat stenting
0.0026 Beta [12, 28–40]
0.02 Beta Assumption
0.02 Beta Assumption, inverse probability
of percutaneous treatment
0.01 Beta [10]
0.0301 Beta [31, 32]
0.0286 Beta [30, 32]
0.02 Beta Assumption, based on literature
[30–32, 40]
0.02 Beta Assumption, inverse probability of
reintervention for aortic wall injury
0.01 Beta [10]
0.1051 Beta [28, 31, 32, 38]
0.0413 Beta [12, 28, 29, 31, 33, 34, 36, 38, 39]
0.02 Beta Assumption, based on literature
[12, 28, 29, 31–34, 36, 38, 39]
0.02 Beta Assumption, inverse probability of
reintervention for aortic wall injury
Table 2 Cost estimates
Item Estimate (£) SD Distribution Source Comment
Stenting for CoA £4507.72 £2612.84 Gamma [41] Currency codes YR12Z; YR13Z; YR14A;
YR14B; YR15A; YR15B; YR15C
Surgery for CoA £7497.61 £5600.01 Gamma [41] Currency codes EC01A; EC01B; EC01C;
EC02A; EC02B; EC02C; EC03A; EC03B; EC03C
Aortic wall injury requiring interventional
treatment
£10 913.59 £5790.90 Gamma [41] Currency codes YR01Z; YR02Z; YR20Z
Aortic wall injury requiring surgery £8545.20 £2305.29 Gamma [41] Currency codes YQ01A; YQ01B; YQ02Z;
YQ03A; YQ03B
Follow-up imaging £5660.04 £1698.01 Gamma [41] Currency code YZ04Z
Hypertension medication £67.53 £20.26 Gamma [42] Average cost per patient per year.
Medication plus annual check-up with GP.
Adjusted to 2014 prices.
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used pooled estimates for aortic wall injuries after stent-
ing; overall reintervention rates at short- and mid-term
follow-up; and the proportion of patients requiring
anti-hypertensive medication at short- and mid-term
follow-up. Our data were based on studies that were
randomized controlled trials with a minimum of 50 partic-
ipants, or other study designs with at least 50 participants
and that were conducted in high income countries.
Additional details are available elsewhere [9].
We made assumptions about the proportion of pa-
tients undergoing repeat stenting (as opposed to sur-
gery) after unsuccessful initial stenting repair; the
proportion of patients receiving percutaneous treatment
(as opposed to surgery) after aortic wall injury; and the
proportion of patients requiring reintervention due to
aortic wall injury (as opposed to recurrent CoA) in both
short-term and mid-term follow-up periods of the
model. Sensitivity of our findings to assumptions was ex-
tensively tested, as described below.
Cost estimates
Our model adopted the health care provider’s perspec-
tive and included direct costs only.
Cost estimates for the treatment of CoA and compli-
cations arising from the initial treatment are based pri-
marily on United Kingdom National Health Service
(NHS) reference costs 2013-14. The NHS provides the
average unit treatment costs for every fiscal year, col-
lected from all NHS trusts. Reference costs reflect the
full costs of providing services [13]. NHS reference costs
do not distinguish between reasons for admissions. To
obtain estimates for cost input parameters we first iden-
tified all relevant variants of treatments (currency codes).
For each cost item in our model we then calculated aver-
age costs from the currency codes relating to that item.
We weighted average costs with the number of health-
care resource groups (HRG) performed annually. Forexample, we obtained an estimate of the cost of stenting
for CoA by adding up all treatments with stents in per-
ipheral arteries (non-coronary stents) and subsequently
weighting them based on their frequency. Our cost esti-
mates are likely to be conservative as they are based on
all patients undergoing any given intervention instead of
exclusively CHD patients who are typically complex
cases with multiple comorbidities.
All costs were discounted at the standard NHS dis-
count rate of 3.5% per year. Where necessary we ad-
justed costs to 2014 Great British Pounds. We assumed
health care costs to increase 2 percentage points above
annual inflation rate [14].
Analytic strategy
The primary outcome of our analysis was expected
avoidable cost associated with stenting in patients with
CoA. In our base case analysis, we calculated the ex-
pected costs for the immediate treatment period, ex-
pected costs at short-term follow-up, and expected costs
at mid-term follow-up by multiplying the event prob-
abilities with their associated costs in each branch of the
model. We then summed the expected costs from the
three periods to obtain an estimate of the total expected
costs. We discounted the expected costs at short-term
and mid-term follow-up at 3.5% p.a.
We compared the costs of this Baseline scenario, in-
cluding costs incurred by complications and other un-
desired events, with the costs that would incur if no or
fewer undesired events occurred [15, 16]. We refer to
the difference between the baseline cost estimate and
the cost estimate in such scenario as the avoidable costs
associated with stenting for CoA. In addition to the
Baseline scenario, we specified four scenarios with vary-
ing rates of hypothetical treatment success and rates of
complications (Fig. 2). We calculated expected avoidable
costs compared to the Baseline scenario for each of the
four scenarios.
Fig. 2 Input probabilities for scenarios. Figure shows probabilities of events subject to change in the four scenarios compared to the Baseline
scenario (red line). No bar shown for Best-case scenario for aortic wall injury; reintervention; and hypertension because the probability for these
events is 0.0% in this scenario
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In the first scenario, the proportion of patients with initial
treatment success remains constant at the baseline value of
96.7%. Proportion of patients with aortic wall injuries
decreases by 10% to 0.7%. Proportion of patients with
reinterventions at follow-up decreases by 10% to 8.2% at
short-term and 16.7% at mid-term follow-up. Hypertension
medication is required by the baseline proportion of 43.0%
of patients at short-term and 38.9% at mid-term follow-up.
Scenario 2
Scenario 2 assumes a constant initial treatment success
rate. Both aortic wall injuries and follow-up reinterven-
tions are assumed to be reduced by 25% from baseline.
Proportion of patients with aortic wall injuries is 0.6% in
this scenario. Reintervention rates at short-term and
mid-term follow-up are 6.8% and 13.9%, respectively.
Furthermore, a 10% reduction in the proportion of pa-
tients requiring anti-hypertensive medication to 38.7% at
short-term and 35.0% at mid-term follow-up is assumed.
Scenario 3
In the third scenario, the initial treatment success rate in-
creases to 100%. Aortic wall injuries are reduced by 50%
from baseline to a proportion of 0.4% of patients. Reinter-
ventions at follow-up are also reduced by 50% from baseline,
leading to values of 4.6% at short-term and 9.3% at mid-
term follow-up. The proportion of patients requiring anti-
hypertensive medication is assumed to be reduced by 25%
to 32.3% at short-term and 29.2% at mid-term follow-up.
Best-case scenario
Finally, we calculate the costs of stenting for CoA under
ideal conditions. In this scenario, treatment success is100%, with no complications during the initial treatment
and at follow-up. The scenario assumes that no reinter-
ventions are necessary and that no patient requires anti-
hypertensive medication.
Sensitivity analysis
Deterministic sensitivity analysis We conducted one-
way sensitivity analyses. We varied key probability and
cost inputs by 10% and plotted the effect on costs avoided
compared to baseline, in a tornado diagram. The tornado
diagram presents the relative impact that each input factor
has on the outcome, holding all other variables constant.
We then varied input variables for all five scenarios to as-
sess the sensitivity of the model with respect to (1) the over-
all level of input values, and (2) the expected avoidable costs
in the scenarios relative to the Baseline scenario. Holding all
other parameters constant, we inspected the extent to
which each parameter had an impact on the difference in
avoidable costs in the four scenarios. We did not include
the Best-case scenario in one-way sensitivity analyses of pa-
rameters that were assumed to be ideal (i.e. 100% treatment
success and 0% complication rates) in this scenario.
We chose a range from 0 to twice the initial input
value for event probabilities and half to twice the initial
value for costs in most cases.
Probabilistic sensitivity analysis We conducted prob-
abilistic sensitivity analysis (PSA) to simultaneously take
into account the uncertainty associated with all input
factors in our model.
We generated 1000 random values for each input par-
ameter based on its point estimate and standard devi-
ation (SD). We assigned a beta distribution to event
probabilities and a gamma distribution to cost estimates.
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for probabilities, and to non-negative values for costs.
SD for cost estimates were derived from published NHS
reference costs for procedures at the aggregate level,
which did not show much variation, potentially under-
estimating SD. We assessed the impact of potentially
underestimated SD of cost parameters on our primary
outcome, avoidable costs, by rerunning PSA with in-
flated SD (twice the initial value).
We then ran 1000 iterations of the model. Each iter-
ation used a different value of the random value distri-
bution of input parameters. We summarized the results
of PSA using the mean value of the 1000 iterations and
its 95% confidence interval (CI). We also present all
1000 PSA estimates of total costs for each of the scenar-
ios (including Baseline) in a single diagram, which dem-
onstrates the uncertainty surrounding estimates of total
costs in the model.
The model and sensitivity analyses were implemented
in Microsoft Excel (Microsoft; Redmond, WA).Results
Results of base-case analysis
Expected costs per patient at initial treatment, short-
term, and mid-term, as well as overall expected costs are
displayed for Baseline, Scenarios 1 to 3, and Best-case
scenario in Table 3. The last row shows expected avoid-
able costs compared to Baseline for all four scenarios.
We calculated the overall expected costs per patient as
£16 688 ($25 181; exchange rate per December 4, 2015).
Expected overall costs in Scenario 1 were £16 551 ($24
975) with avoidable costs amounting to £137 ($207).
Scenario 2 showed slightly lower overall costs (£16
338/$24 654) and conversely higher savings from avoid-
able costs (£350/$528). Optimistic assumptions in
Scenario 3, including a 100% initial treatment success
rate, brought overall expected costs down to £15 790
($23 827) with expected avoidable costs at an estimated
£898 ($1355).
In the Best-case scenario, overall expected costs were
£15 061 ($22 727), translating into £1627 ($2455) in
avoidable costs. The most substantial cost savings com-
pared to Baseline were accumulated at follow-up (£488/
$736 at short-term and £858/$1295 at mid-term), whileTable 3 Results from base-case analysis: expected costs of stenting
Baseline Scenario
Expected costs initial treatment £4790 £4781
Expected costs short-term £5980 £5933
Expected costs mid-term £5919 £5836
Expected costs overall £16,688 £16,551
Expected avoidable costs vs. Baseline £137avoidable costs at the initial treatment amounted to
£282 ($426).
Deterministic sensitivity analysis
The tornado diagram (Fig. 3) shows that cost of imaging
at follow-up; cost of the stenting procedure; and prob-
ability of successful stenting have the largest impact on
total costs, when considering a 10% increase or decrease
in key model parameters while holding all other parame-
ters constant.
We assessed the sensitivity of expected avoidable costs
in the four scenarios with respect to all model input pa-
rameters. We only display results of univariate analysis
for stenting treatment success and reintervention rates.
Sensitivity analyses of all parameters are available in the
Additional file 1 (section A3).
Figure 4 displays expected avoidable costs in Scenarios
1–3 and the Baseline scenario when varying treatment
success rate from a decrease by 100% from the initial
value to an increase by 20%. At the initial input level
there were no expected avoidable costs in the Baseline
scenario and the maximum avoidable costs were seen in
Scenario 3 at £898 (Best-case scenario, at a constant suc-
cess rate of 100%, was not included in the sensitivity
analysis). Even when varying treatment success rates to
the extreme values of 0 and 100%, the results for max-
imum avoidable costs did not differ substantially from
that obtained with the initial input value. At a rate of 0%
treatment success, total costs in all four scenarios were
considerably higher. The difference in total costs, how-
ever, decreased only slightly (from £898 to £680 between
Baseline and Scenario 3). The estimates for all four sce-
narios reached a floor at treatment success improvement
rates over 3.5%, as this coincided with achieving treat-
ment success in 100% of patients.
At the extremes of the sensitivity analysis for reinter-
ventions at follow-up, we observed significant differences
between the magnitude of avoidable costs associated
with the four scenarios (Fig. 5). Compared to avoidable
costs of £898 in Scenario 3 associated with the initial
parameter values, the difference in total costs between
the Baseline scenario and Scenario 3 was £258 when 0%
of patients required reinterventions at follow-up, and in-
creased to £1538 when the estimate was set to twice its
initial value.for CoA and avoidable costs in four scenarios
1 Scenario 2 Scenario 3 Best-case scenario
£4769 £4550 £4508
£5861 £5741 £5492
£5709 £5498 £5061
£16,338 £15,790 £15,061
£350 £898 £1627
Fig. 3 Tornado diagram
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After 1000 iterations of the model using random values
drawn from relevant distributions for each input param-
eter, mean estimated avoidable costs were similar to ex-
pected avoidable costs in the deterministic base case
analysis (Fig. 6). This is particularly true for Scenarios 2,
3, and Best-case, where only small deviations occurred
in point estimates between base case analysis and PSA.
Avoidable costs in Scenario 1 were estimated at £259
(95% CI 71-622) in PSA compared to £137 in the base
case analysis.Fig. 4 Univariate sensitivity analysis for stenting success. The diagram show
(horizontal axis) and expected total costs compared to the initial input value (
values of treatment success are displayed relative to the initial input (96.7% trThe results of PSA show a wide overlap of 95% CIs be-
tween avoidable costs in Scenarios 1 and 2, and to some
extent between Scenarios 2 and 3. There was minimal
overlap in the 95% CIs between Scenario 1 and Best-
case (full results of PSA for all scenarios shown in
Additional file 1, section A1).
PSA of total costs showed wide overlap between the
Baseline scenario and all four scenarios (Fig. 7). Total
costs in the Best-case scenario were 90.2% of costs in the
Baseline scenario. Potential cost savings in the other sce-
narios ranged from 1.6 to 5.4% of total costs at baseline.s the relationship between varying probabilities for treatment success
vertical axis) in Scenarios 1–3, as well as the Baseline scenario. Varying
eatment success)
Fig. 5 Univariate sensitivity analysis for follow-up reinterventions. The diagram shows the relationship between varying probabilities for
reinterventions at follow-up (horizontal axis) and expected total costs compared to the initial input value (vertical axis) in Scenarios 1–3,
as well as the Baseline scenario. Varying values of reintervention rates are displayed relative to the initial input of 9.1% at short-term and
18.5% at mid-term follow-up
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not reveal a significant impact on our main results. After
inflating SD of all cost parameters to twice their initial
value mean expected avoidable costs in the four scenar-
ios did not deviate from the results obtained with un-
adjusted SD (results of SD sensitivity analysis shown in
Additional file 1, section A2).Fig. 6 Estimated avoidable costs in four scenarios; probabilistic sensitivity ana
Baseline, with bars indicating 95% CIs. Red circles show estimates of the baseDiscussion
Proposals for cost reduction in health care are often
met with skepticism. Cost cuts are often perceived to
be associated with lower staff-per-patient ratios, re-
duced investment and, consequently, worse quality in
care provision. However, high treatment costs are not
necessarily a reliable indicator of high quality [17].lysis. Blue circles represent mean expected avoidable costs compared to
-case analysis
Fig. 7 Estimated total costs; probabilistic sensitivity analysis. Results of PSA of total costs at Baseline and in four scenarios. Each circle represents
expected total costs in one of n = 1000 iterations. Red bars show the mean result of iterations
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meet any resistance: sub-optimal provision of care and
complications associated with treatments are both harm-
ful (for patients) and costly. Berwick and colleagues esti-
mated the annual cost of failures of care delivery in the
US health care system between $102 and $154 billion [18].
Costs associated with theoretically avoidable complica-
tions and potential room for improvement in effectiveness
can be labelled as avoidable costs and provide an attractive
target for cost reduction efforts. Simultaneous cost savings
and improvement of patient outcomes have been demon-
strated in various settings [19–22].
To the best of our knowledge, this analysis of avoid-
able costs in stenting therapy for patients with CoA is
the first to examine the potential for cost savings
through increased treatment effectiveness in CHD.
We found that significant improvements in treatment
effectiveness are required to achieve discernible cost sav-
ings. Initial treatment success of stenting in patients
with CoA is already very high, limiting the scope for
improvements in treatment effectiveness and accom-
panying cost reductions from averted repeat proce-
dures. The tornado diagram suggested that cost of
imaging at follow-up; cost of the stenting procedure;
and probability of successful stenting had the largestimpact on total costs. This is not surprising given
that all patients in the model undergo both stenting
and imaging at follow-up. Varying values for the cost
of the stenting procedure and follow-up imaging im-
pact on the overall cost levels, but possess little influ-
ence on avoidable costs as defined in our analysis.
Our analysis identified reinterventions at follow-up as
the most important lever for achieving cost savings.
Aneurysm formation and recurrent CoA, along with
hypertension, have long been identified as weaknesses
of CoA repair [23]. We observe that reinterventions
due to aortic wall injuries and recurrent CoA are also
the main drivers of avoidable costs in stenting repair
of CoA.
If discernible savings through the reduction of poten-
tially avoidable adverse outcomes are to be realized, clin-
ical practice has to approach the best-case scenario.
Personalized treatment decisions through the use of in-
dividual patient data are a promising path towards treat-
ment optimization. Stenting is an accepted treatment
option for CoA but details of the intervention, including
choice of stent type and length, as well as timing of the
intervention, are likely to be best decided for each pa-
tient individually. Treatment decisions must take into
account the patient’s age, anatomy, treatment history,
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tual Physiological Human (VPH) projects have the po-
tential to move clinical practice towards increasingly
individualized and patient-centered treatment decisions
with better patient outcomes. Just as in other areas of
personalized medicine, potential benefits are manifold
and include improving mortality and morbidity, and re-
ducing health care expenditures. In patients with CoA,
image-based modelling of the aorta was recently used to
create a virtual stenting tool which could aid clinical
decision-making by simulating post-treatment blood
flows in various scenarios [24, 25]. Given the overall
good performance of stenting repair of CoA, cost effect-
iveness of this approach will be conditional on improved
identification of selected, high-risk populations for
whom tailored interventions can prevent future high-
cost complications and treatments.
Overall, the overall scope for cost savings from im-
proved treatment outcomes in patients undergoing
stenting for CoA is small. Cost savings per patient were
£137, £350, and £898 in Scenarios 1, 2, and 3, respect-
ively. In the United States, an estimated 521 stenting
procedures are conducted annually in patients with CoA
[26]. Under the assumptions that prevalence of CoA is
similar in the United Kingdom and the United States,
and that procedure frequency is relative to total popula-
tion, a back of the envelope calculation reveals cost sav-
ings for the NHS of £14 522 in Scenario 1, £37 100 in
Scenario 2, and £95 188 in Scenario 3 over 5 years for
106 patients yearly.
Limitations
Our analysis was limited by the data available to model
undesirable outcomes at follow-up. We included reinter-
ventions due to aortic wall injuries and recurrent CoA
as well as antihypertensive medication therapy but did
not account for other complications that might occur
late after CoA repair due to limited data availability.
Similarly, it was not always possible to include estimates
of event probabilities from meta-analyses or large trials
due to limited availability of such studies and some of
the parameters of our model were therefore based on as-
sumptions informed by reports in the literature. Our
model was also restricted to a 5-year period. Long-term
follow-up studies of patients undergoing stenting are still
relatively rare and often conducted retrospectively in
small cohorts. For example, long-term studies are re-
quired to assess the consequences of exercise-induced
hypertension after CoA repair [27].
It is unclear through which mechanisms the improve-
ments in the quality of care for patients with CoA in-
cluded in our scenario analysis would be achieved and
whether such improvements are realistic. For example,
whether or not CoA repair can resolve hypertension inpatients with CoA remains elusive. Perfect outcomes in
all patients, as modeled the Best-case scenario, might
never be accomplished. However, our study was de-
signed not only to demonstrate what could realistic-
ally be achieved, but also to demonstrate the absolute
maximum in cost savings associated with stenting re-
pair of CoA.
We focused on costs and events that were related
to stenting repair of CoA. We did not aim to obtain
estimates of all costs and events associated with CoA.
Expected costs of stenting for CoA repair therefore
do not represent a true estimate of all costs associ-
ated with the disease.
Cost estimates were restricted to aggregate level infor-
mation from the United Kingdom NHS reference costs.
It is possible that mean costs of procedures are higher
for patients with CHD than other patients due to co-
morbidities. A potential systematic underestimation of
all cost parameters included in the model has implica-
tions for the overall cost level but should not affect rela-
tive comparisons of avoidable costs in the specified
scenarios. PSA results demonstrated a considerable de-
gree of uncertainty associated with the results of the
model, which stems from relatively small potential cost
savings compared to total costs as well as from uncer-
tainty in input parameters. Total costs in the four sce-
narios ranged from 98.5 to 90.2% of Baseline costs.
We derived SD for cost estimates from aggregate cost
items in the NHS reference costs. It is therefore possible
that SD were underestimated for the procedures in-
cluded in the model. Apart from the expected increase
in variance, inflating SD to twice their initial value did
not change our results.
Conclusion
We examined the potential cost savings associated with
improvement in effectiveness and reduction of complica-
tions in stenting treatment of aortic coarctation. The
biggest potential for cost savings lies in improving the
endurance of therapies, and thus the reduction of rein-
tervention rates at follow-up. Significant improvements
in the treatment effectiveness and reductions in compli-
cation rates are required to realize discernible cost sav-
ings. Up to 10% of total baseline costs could be avoided
in the best-case scenario. This highlights the need to
pursue patient-specific treatment approaches which
promise optimal outcomes. The individualization of
treatment procedures with the help of disease specific
modeling can already help to select the most relevant
stenosis and to find an optimal location for interven-
tional treatment. Further advances in modelling will po-
tentially enable physicians to identify patients with high
risk of treatment failure and prevent costly complica-
tions and follow-up treatment in those.
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Additional file 1: The supplemental material provides additional
information on model inputs and results of the extensive sensitivity
analyses conducted. The supplemental material is provided in one
document under the following section headings: A1. Results of
probabilistic sensitivity analysis. A2. Calculation of cost inputs and
standard deviations. A3. Univariate sensitivity analyses of all input
parameters. (PDF 1.14 mb)
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